Independent, The (London) - US approves Glaxo drug for Parkinson
Business News IN BRIEF
Related Results
GSK faces approval delay.
GSK wins restless leg race
Research and Markets: The Parkinsons Disease Market Is Set To Continue To Gro…
PPSI wins SW Argus press revamp work
Pinguin sauve une usine anglaise de legumes surgeles. (En Manchete Dans Ce Nu…
*The British pharmaceuticals giant Glaxo has won US approval for its Parkinson’s disease treatment, Requip XL. The once-a-day drug uses SkyePharma’s Geomatrix technology to give continuous delivery over 24 hours. SkyePharma’s shares soared 32 per cent to 7.25p, while Glaxo shares rose 1 per cent to 10.87. The US launch of Requip XL, which is already approved in Europe, is expected by July. An older version of Requip is already approved for Parkinson’s and restless leg syndrome. Requip had worldwide sales of 94m in the first quarter, with US revenues accounting for 60m.
Copyright c 2008 Independent Newspapers UK Limited. All rights
owned or operated by The Independent.
Provided by ProQuest Information and Learning Company. All rights Reserved.
